<DOC>
	<DOCNO>NCT02200315</DOCNO>
	<brief_summary>The aim study evaluate feasibility safety use antimicrobial prophylaxis laparoscopic distal gastrectomy gastric carcinoma .</brief_summary>
	<brief_title>No Antimicrobial Prophylaxis Laparoscopic Distal Gastrectomy</brief_title>
	<detailed_description>This phase II clinical trial investigate postoperative surgical site infection ( SSI ) rate antimicrobial prophylaxis use laparoscopic distal gastrectomy . Target range SSI rate laparoscopic distal gastrectomy determine base previous report data . If SSI rate within target range , investigator proceed randomize controlled trial investigate efficacy antimicrobial use laparoscopic gastrectomy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Histologically proven gastric adenocarcinoma clinical stage T12N0M0 patient underwent laparoscopic distal gastrectomy Age 18 65 year American Society Anaesthesiologists ( ASA ) status &gt; 2 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Normal blood , liver , pulmonary , cardiac , renal function Informed consent Administration antibiotic within 1 month surgery Active infection time surgery Combined resection operation ( i.e. , spleen , liver , colon , etc . ) History upper abdominal surgery Previous chemotherapy radiotherapy within 6 month surgery Uncontrolled underlying comorbidities Malnutrition BMI le 18.5 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Stomach neoplasm</keyword>
	<keyword>Surgical site infection</keyword>
	<keyword>Laparoscopic gastrectomy</keyword>
	<keyword>Antimicrobial prophylaxis</keyword>
</DOC>